Department of Endocrinology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China.
Department of Thyroid Surgery, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Nat Commun. 2024 Jul 19;15(1):5555. doi: 10.1038/s41467-024-49824-7.
Neurotransmitters are key modulators in neuro-immune circuits and have been linked to tumor progression. Medullary thyroid cancer (MTC), an aggressive neuroendocrine tumor, expresses neurotransmitter calcitonin gene-related peptide (CGRP), is insensitive to chemo- and radiotherapies, and the effectiveness of immunotherapies remains unknown. Thus, a comprehensive analysis of the tumor microenvironment would facilitate effective therapies and provide evidence on CGRP's function outside the nervous system. Here, we compare the single-cell landscape of MTC and papillary thyroid cancer (PTC) and find that expression of CGRP in MTC is associated with dendritic cell (DC) abnormal development characterized by activation of cAMP related pathways and high levels of Kruppel Like Factor 2 (KLF2), correlated with an impaired activity of tumor infiltrating T cells. A CGRP receptor antagonist could offset CGRP detrimental impact on DC development in vitro. Our study provides insights of the MTC immunosuppressive microenvironment, and proposes CGRP receptor as a potential therapeutic target.
神经递质是神经免疫回路的关键调节剂,与肿瘤进展有关。髓样甲状腺癌(MTC)是一种侵袭性神经内分泌肿瘤,表达神经递质降钙素基因相关肽(CGRP),对化疗和放疗不敏感,免疫疗法的效果尚不清楚。因此,对肿瘤微环境进行全面分析将有助于制定有效的治疗方法,并为 CGRP 在神经系统之外的功能提供证据。在这里,我们比较了 MTC 和甲状腺乳头状癌(PTC)的单细胞图谱,发现 MTC 中 CGRP 的表达与树突状细胞(DC)的异常发育有关,其特征是 cAMP 相关途径的激活和高水平的 Kruppel 样因子 2(KLF2),与肿瘤浸润 T 细胞活性受损有关。CGRP 受体拮抗剂可以抵消 CGRP 对体外 DC 发育的不利影响。我们的研究提供了对 MTC 免疫抑制微环境的深入了解,并提出 CGRP 受体作为潜在的治疗靶点。